CC
ADPT icon

Crosslink Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Crosslink Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,000
Closed -$242K – 24
2019
Q2 		$242K Buy
+5,000
New +$222K 0.06% 26

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crosslink Capital's ADPT Position: Q3 2019 in Review

Crosslink Capital sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 5,000 shares — an estimated $242K sold.

Crosslink Capital first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $242K in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

  • Crosslink Capital reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Crosslink Capital sold 5,000 Adaptive Biotechnologies shares in Q3 2019, an estimated $242K.
  • Crosslink Capital first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
  • Crosslink Capital's Adaptive Biotechnologies position peaked at $242K in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on Crosslink Capital's 13F filing for Q3 2019, filed 14 Nov 2019.